Form 8-K
8-K — NU SKIN ENTERPRISES, INC.
Accession: 0001140361-26-032025
Filed: 2026-08-10
Period: 2026-08-10
CIK: 0001021561
SIC: 5122 (WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — ef20079831_8k.htm (Primary)
EX-99.1 — PRESS RELEASE DATED AUGUST 10, 2026 (ef20079831_ex99-1.htm)
GRAPHIC (image00001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: ef20079831_8k.htm · Sequence: 1
false000102156100010215612026-08-102026-08-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 10, 2026
Date of Report (Date of earliest event reported)
NU SKIN ENTERPRISES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-12421
87-0565309
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
75 West Center Street
Provo, Utah 84601
(Address of principal executive offices and zip code)
(801) 345-1000
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
NUS
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On August 10, 2026, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three- and six-month periods ended June 30,
2026, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.
The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
99.1
Nu Skin Enterprises’ press release dated August 10, 2026, regarding financial results for the three- and six-month periods ended June 30, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NU SKIN ENTERPRISES, INC.
(Registrant)
/s/ Chelsea K. Lantz
Chelsea K. Lantz
Chief Financial Officer
Date: August 10, 2026
EX-99.1 — PRESS RELEASE DATED AUGUST 10, 2026
EX-99.1
Filename: ef20079831_ex99-1.htm · Sequence: 2
Exhibit 99.1
FOR IMMEDIATE RELEASE
Nu Skin Enterprises Reports Second Quarter Results
PROVO, Utah — Aug. 10, 2026 — Nu Skin Enterprises
Inc. (NYSE: NUS) today announced second quarter results.
Executive Summary
Q2 2026 vs. Prior-year Quarter
Revenue
$320.1 million; (17.1)%
• (1.0)% FX impact
or $(4.0) million
Earnings Per Share (EPS)
$(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43
Customers
660,037; (14)%
Paid Affiliates
120,291; (8)%
Sales Leaders
26,998; (9)%
“We continue to make progress toward our long-term strategy with the continued rollout of Prysm iO and preparations for the formal launch of India,” said Ryan Napierski, Nu
Skin president and CEO. “As these initiatives are taking hold, we are incorporating valuable learnings to strengthen our plans moving forward. At the same time, we are re-aligning our organizational resources to better position the business to drive
sustainable, long-term value for our shareholders.”
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 2
Q2 2026 Year-over-year Operating Results
Revenue
$320.1 million compared to $386.1 million
• (1.0)% FX impact
or $(4.0) million
Gross Margin
68.2% compared to 68.8%
• Nu Skin business
was 77.7% compared to 77.5%
Selling Expenses
33.7% compared to 33.2%
• Nu Skin business
was 39.8% compared to 40.0%
G&A Expenses
28.4% compared to 27.6%
Operating Margin
(18.5)% or 6.1% excluding non-cash impairment charge compared to 8.0%
Interest Expense
$3.3 million compared to $2.5 million
Other Income (Expense)
$(0.5) million compared to $(0.8) million
Income Tax Rate
(295.4)% or 36.6% excluding non-cash tax charge compared to 23.0%
EPS
$(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43
Stockholder Value
Dividend Payments
$2.9 million
Stock Repurchases
$0.0 million
• $137.3 million
remaining in authorization
Q3 and Full-year 2026 Outlook
Q3 2026 Revenue
$310 to $340 million; (15)% to (7)%
• Approximately
(3) to (2)% FX impact
Q3 2026 EPS
$0.00 to $0.09 or $0.10 to $0.20 on an adjusted basis
2026 Revenue
$1.28 to $1.35 billion; (14)% to (9)%
• Approximately
(1)% FX impact
2026 EPS
($4.90) to ($4.73) or $0.70 to $0.90 on an adjusted basis
“We delivered adjusted earnings per share near the
midpoint of our guidance, reflecting our ongoing focus on profitability and disciplined execution,” said Chelsea Lantz, interim chief financial officer. “Based on our first-half
performance and outlook for the rest of the year, we are updating our annual guidance to revenue of $1.28 billion to $1.35 billion and adjusted earnings per share of $0.70 to $0.90. For the third quarter, we expect revenue between $310 million
and $340 million, with adjusted earnings per share in the range of $0.10 to $0.20.”
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 3
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the
webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 24, 2026.
About Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products
help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment
arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the
company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s
expectations regarding the company’s performance, growth, initiatives, shareholder value, Prysm launch and its timing, and India expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency
fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as
“believe,” “expect,” “become,” “drive,” “project,” “outlook,” “guidance,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially
from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
•
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a
sustained basis;
•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner
that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions,
imposition of fines, or any other adverse actions or events;
•
economic conditions and events globally;
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 4
•
the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and
any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;
•
competitive pressures in the company’s markets;
•
risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
•
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
•
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business
operations and results;
•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
•
uncertainties regarding the future financial performance of the businesses the company has acquired;
•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of
inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a
market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty
to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures:
Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by
translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue
change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.
Earnings per share, operating margin, and income tax rate, each excluding impairment charges, tax charges, and/or other charges, also are non-GAAP
financial measures.
•
Impairment charges and the tax charge incurred in the second quarter of 2026 are not part of the ongoing operations of our underlying business; and
•
The other charges incurred in connection with certain corporate actions, as described in the footnotes to the non-GAAP reconciliation tables below, are not part of our ongoing
operations.
The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items
facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 5
The following table sets forth revenue for the three-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):
Three Months Ended
June 30,
Constant-
Currency
Change
2026
2025
Change
Nu Skin
Americas
$
59,763
$
72,946
(18.1
)%
(15.8
)%
Mainland China
45,956
53,224
(13.7
)%
(18.7
)%
Southeast Asia/Pacific
43,257
50,834
(14.9
)%
(16.3
)%
Japan
38,143
44,550
(14.4
)%
(5.5
)%
Europe & Africa
32,317
37,328
(13.4
)%
(15.2
)%
Hong Kong/Taiwan
26,074
27,527
(5.3
)%
(3.6
)%
South Korea
25,620
34,068
(24.8
)%
(19.0
)%
Nu Skin Other
79
427
(81.5
)%
(81.5
)%
Total Nu Skin
271,209
320,904
(15.5
)%
(14.2
)%
Rhyz
Manufacturing
46,369
60,400
(23.2
)%
(23.2
)%
Rhyz Other
2,534
4,834
(47.6
)%
(47.6
)%
Total Rhyz
48,903
65,234
(25.0
)%
(25.0
)%
Total
$
320,112
$
386,138
(17.1
)%
(16.1
)%
The following table sets forth revenue for the six-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):
Six Months Ended
June 30,
Constant-
Currency
Change
2026
2025
Change
Nu Skin
Americas
$
117,581
$
142,004
(17.2
)%
(14.2
)%
Mainland China
91,104
100,999
(9.8
)%
(14.6
)%
Southeast Asia/Pacific
88,731
103,006
(13.9
)%
(16.5
)%
Japan
77,882
87,315
(10.8
)%
(4.9
)%
Europe & Africa
63,535
70,349
(9.7
)%
(15.0
)%
Hong Kong/Taiwan
53,531
55,974
(4.4
)%
(4.8
)%
South Korea
50,949
66,583
(23.5
)%
(20.2
)%
Nu Skin Other
(155
)
956
(116.2
)%
(116.2
)%
Total Nu Skin
543,158
627,186
(13.4
)%
(13.4
)%
Rhyz
Manufacturing
91,294
115,690
(21.1
)%
(21.1
)%
Rhyz Other
6,268
7,752
(19.1
)%
(19.1
)%
Total Rhyz
97,562
123,442
(21.0
)%
(21.0
)%
Total
$
640,720
$
750,628
(14.6
)%
(14.6
)%
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 6
The following tables provide information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods
ended June 30, 2026 and 2025.
Three Months Ended
June 30,
Change
2026
2025
Customers
Americas
183,757
240,477
(24
)%
Mainland China
103,891
117,325
(11
)%
Southeast Asia/Pacific
69,354
72,814
(5
)%
Japan
100,849
105,961
(5
)%
Europe & Africa
111,332
126,146
(12
)%
Hong Kong/Taiwan
36,549
41,371
(12
)%
South Korea
54,305
67,313
(19
)%
Total Customers
660,037
771,407
(14
)%
Paid Affiliates
Americas
27,337
28,827
(5
)%
Mainland China
18,736
19,399
(3
)%
Southeast Asia/Pacific
17,677
21,092
(16
)%
Japan
19,018
19,605
(3
)%
Europe & Africa
13,307
15,320
(13
)%
Hong Kong/Taiwan
9,390
9,570
(2
)%
South Korea
14,826
16,986
(13
)%
Total Paid Affiliates
120,291
130,799
(8
)%
Sales Leaders
Americas
5,041
5,971
(16
)%
Mainland China
5,899
5,790
2
%
Southeast Asia/Pacific
3,631
4,126
(12
)%
Japan
5,782
5,882
(2
)%
Europe & Africa
2,216
2,695
(18
)%
Hong Kong/Taiwan
1,858
2,063
(10
)%
South Korea
2,571
3,066
(16
)%
Total Sales Leaders
26,998
29,593
(9
)%
•
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our salesforce who made such a
purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
•
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides
Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.
•
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as
of the end of each month of the quarter.
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 7
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Revenue
$
320,112
$
386,138
$
640,720
$
750,628
Cost of sales
101,787
120,405
207,932
237,934
Gross profit
218,325
265,733
432,788
512,694
Operating expenses:
Selling expenses
107,922
128,228
217,976
246,774
General and administrative expenses
90,847
106,725
189,391
219,929
Impairment expenses
78,875
-
80,714
25,114
Total operating expenses
277,644
234,953
488,081
491,817
Operating income (loss)
(59,319
)
30,780
(55,293
)
20,877
Interest expense
3,322
2,526
7,572
5,809
Gain on sale of business
-
-
-
176,162
Other income (expense), net
(534
)
(843
)
2,289
(29,218
)
Income (loss) before provision for income taxes
(63,175
)
27,411
(60,576
)
162,012
Provision for income taxes
186,623
6,292
187,386
33,378
Net income (loss)
$
(249,798
)
$
21,119
$
(247,962
)
$
128,634
Net income (loss) per share (Note 7):
Basic
$
(5.14
)
$
0.43
$
(5.12
)
$
2.59
Diluted
$
(5.14
)
$
0.43
$
(5.12
)
$
2.59
Weighted-average common shares outstanding (000s):
Basic
48,596
49,441
48,400
49,601
Diluted
48,596
49,499
48,400
49,748
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 8
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
June 30,
2026
December 31,
2025
ASSETS
Current assets:
Cash and cash equivalents
$
189,643
$
238,630
Current investments
1,743
1,211
Accounts receivable, net
48,902
39,544
Inventories, net
191,497
178,643
Prepaid expenses and other
76,364
89,670
Total current assets
508,149
547,698
Property and equipment, net
379,550
377,168
Operating lease right-of-use assets
65,442
74,021
Goodwill
4,750
83,625
Other intangible assets, net
37,884
42,614
Other assets
125,755
280,187
Total assets
1,121,530
1,405,313
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$
37,711
$
26,183
Accrued expenses
198,636
217,551
Current portion of long-term debt
20,000
20,000
Total current liabilities
256,347
263,734
Operating lease liabilities
50,075
57,640
Long-term debt
193,664
204,187
Other liabilities
78,705
74,512
Total liabilities
578,791
600,073
Commitments and contingencies (Notes 6 and 12)
Stockholders’ equity:
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
91
91
Additional paid-in capital
612,412
635,994
Treasury stock, at cost – 41.9 million and 42.4 million shares
(1,558,183
)
(1,575,059
)
Accumulated other comprehensive loss
(118,152
)
(116,105
)
Retained earnings
1,606,571
1,860,319
Total stockholders' equity
542,739
805,240
Total liabilities and stockholders’ equity
$
1,121,530
$
1,405,313
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 9
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
(in thousands, except for per share amounts)
Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
Operating Income
$
(59,319
)
$
30,780
$
(55,293
)
$
20,877
Impact of inventory write-off
-
-
3,116
-
Impact of other charges(1)
-
-
2,643
7,966
Impact of impairment
78,875
-
80,714
25,114
Adjusted operating income
$
19,556
$
30,780
$
31,180
$
53,957
Operating margin
(18.5
)%
8.0
%
(8.6
)%
2.8
%
Operating margin, excluding certain charges
6.1
%
8.0
%
4.9
%
7.2
%
Revenue
$
320,112
$
386,138
$
640,720
$
750,628
(1) Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of
other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation
as a result of the vesting of the Mavely profits interest units.
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 10
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Certain Charges to GAAP Effective Tax Rate
(in thousands, except for per share amounts)
Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
Provision (benefit) for income taxes
$
186,623
$
6,292
$
187,386
$
33,378
Impact of inventory write-off on provision for income taxes
-
-
1,065
-
Impact of other charges(1) on provision for income taxes
-
-
903
725
Impact of impairment on provision for income taxes
(13,370
)
-
(12,741
)
5,433
Impact of gain on Mavely sale on provision for income taxes
-
-
-
(31,104
)
Impact of gain on unrealized investment loss on provision for income taxes
-
-
-
6,074
Impact of valuation allowance on deferred tax assets
(167,505
)
-
(167,505
)
-
Provision for income taxes, excluding impact of certain charges
$
5,748
$
6,292
$
9,108
$
14,506
Income before provision for income taxes
(63,175
)
27,411
(60,576
)
162,012
Impact of inventory write-off
-
-
3,116
-
Impact of other charges(1)
-
-
2,643
7,966
Impact of impairment expense:
78,875
-
80,714
25,114
Impact of gain on Mavely sale
-
-
-
(176,162
)
Impact of unrealized investment loss
-
-
-
28,077
Income before provision for income taxes, excluding impact certain charges
$
15,700
$
27,411
$
25,897
$
47,007
Effective tax rate
(295.4
)%
23.0
%
(309.3
)%
20.6
%
Effective tax rate, excluding impact of certain charges
36.6
%
23.0
%
35.2
%
30.9
%
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 11
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain
Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)
Three months ended
June 30,
Six months ended
June 30,
2026
2025
2026
2025
Net income
$
(249,798
)
$
21,119
$
(247,962
)
$
128,634
Impact of Inventory write-off
Inventory write-off
-
-
3,116
-
Tax impact
-
-
(1,065
)
-
Impact of other charges
Other charges
-
-
2,643
7,966
Tax impact
-
-
(903
)
(725
)
Impact of impairment
Impairment charges
78,875
-
80,714
25,114
Tax impact
13,370
-
12,741
(5,433
)
Impact of Mavely sale
Mavely sale
-
-
-
(176,162
)
Tax impact
-
-
-
31,104
Impact of unrealized investment loss
Unrealized investment loss
-
-
-
28,077
Tax impact
-
-
-
(6,074
)
Impact of valuation allowance on deferred tax assets
167,505
-
167,505
-
Adjusted net income
$
9,952
$
21,119
$
16,789
$
32,501
Diluted earnings per share
$
(5.14
)
$
0.43
$
(5.12
)
$
2.59
Diluted earnings per share, excluding impact of certain charges
$
0.20
$
0.43
$
0.35
$
0.65
Weighted-average common shares outstanding (000)
48,596
49,499
48,400
49,748
Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 12
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share
Three months ended
September 30, 2026
Year ended December 31, 2026
Low end
High end
Low end
High end
Earnings Per Share
$
0.00
$
0.09
$
(4.90
)
$
(4.73
)
Impact of inventory write-off
Inventory write-off
-
-
0.06
0.06
Tax impact
-
-
(0.02
)
(0.02
)
Impact of other charges
Other charges(2)
0.10
0.10
0.15
0.15
Tax impact
(0.02
)
(0.02
)
(0.04
)
(0.04
)
Impact of impairment:
Impairment charges
-
-
1.67
1.67
Tax impact
-
-
0.26
0.26
Impact of valuation allowance on deferred tax assets
0.02
0.03
3.52
3.55
Adjusted EPS
$
0.10
$
0.20
$
0.70
$
0.90
(2) We are currently anticipating other charges for the third quarter of 2026 of approximately $5 million in cash-based transition cost. Other charges for
the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges.
# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577
GRAPHIC
GRAPHIC
Filename: image00001.jpg · Sequence: 6
Binary file (2995 bytes)
Download image00001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Document and Entity Information
Aug. 10, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 10, 2026
Entity File Number
001-12421
Entity Registrant Name
NU SKIN ENTERPRISES, INC.
Entity Central Index Key
0001021561
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
87-0565309
Entity Address, Address Line One
75 West Center Street
Entity Address, City or Town
Provo
Entity Address, State or Province
UT
Entity Address, Postal Zip Code
84601
City Area Code
801
Local Phone Number
345-1000
Title of 12(b) Security
Class A Common Stock, $.001 par value
Trading Symbol
NUS
Security Exchange Name
NYSE
Entity Emerging Growth Company
false
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration